Siemens Healthineers: Regulatory Gains and Oncology Boost Collide With Diagnostics Drag and India Exit Plans

Despite FDA approvals for AI imaging and oncology advances at ESTRO, Siemens Healthineers cuts full-year guidance as diagnostics slump persists, exploring sale of Indian clinics.

The German medtech group Siemens Healthineers is navigating a starkly divided landscape. While regulatory approvals in the US and a prominent presence at the ESTRO oncology congress in Stockholm underscore its technological momentum, a persistent slump in diagnostics, a cut to full-year guidance, and an impending Indian clinic sale are pulling the stock toward its 52-week low. The shares recently changed hands at €33.60, leaving them down roughly 24% since the start of the year and barely above the trough.

Q2 revenue slips as diagnostics weighs

In the second fiscal quarter of 2026, group revenue fell nearly 4% to €5.68 billion, with adjusted earnings per share also sliding. The main culprit was the diagnostics division, where restructuring in China drove a 6.5% drop in segment sales. Imaging provided a counterweight, posting comparable growth of 6.1% and an operating margin above 22%. Varian, the cancer-care subsidiary, added 7.5% organic expansion.

The weakness prompted management to trim its full-year outlook. Comparable revenue growth is now forecast at 4.5% to 5.0%, with adjusted earnings per share reaching up to €2.30. The diagnostics unit’s adjusted EBIT margin sank to 0.9%, underscoring the urgency of the turnaround.

FDA green lights six AI-powered systems

Amid the operational headwinds, the US Food and Drug Administration cleared six new Artis interventional imaging systems that incorporate the company’s “Optiq AI” deep-learning technology, designed to reduce noise and improve image quality during procedures. Separately, the US Centers for Disease Control and Prevention renewed a key certification for the diagnostics segment, ensuring clinical comparability for hormone tests.

Oncology takes centre stage in Stockholm

At the ESTRO congress, Siemens Healthineers unveiled a series of AI-driven tools under the banner “Elevating Cancer Care.” The highlight is the NAEOTOM Alpha Prime RT Pro Edition, a photon-counting CT scanner tailored for radiation therapy that promises sharper tissue differentiation and lower radiation doses. The company also promoted its AI-Rad Companion software, which automates segmentation of organs and tumours — tackling a bottleneck that consumes scarce clinical time.

Varian, the radiotherapy arm, hosted its own summit for radio-oncology specialists, reinforcing the message that Siemens Healthineers aims to become a platform for integrated treatment planning, imaging, and therapy rather than a mere hardware supplier.

India: a planned exit from oncology clinics

To shore up profitability over the longer term, the group is exploring a sale of its Indian cancer-therapy chain, American Oncology Institute. The transaction, still in an early phase and advised by Alvarez & Marsal, could be valued at between ?15 billion and ?20 billion. Potential buyers include private-equity funds and Healthcare Global Enterprises, a local healthcare operator.

Analysts split on valuation

The mixed signals have produced diverging views on the Street. Deutsche Bank Research rates the stock a “Hold” and cut its price target to €38, urging a swift recovery in margins to sustain 2027 expectations. J.P. Morgan retains an “Overweight” rating but lowered its target in May to €55.80, acknowledging that while imaging and Varian continue to deliver, the diagnostics drag weighs on both sentiment and valuation.

The diagnostic carve-out as a litmus test

With formal separation of the diagnostics unit now on the table, the coming months will show whether the group can relieve the pressure that has kept the share price near its floor. If the restructuring in China and the planned divestiture in India succeed, the AI-led oncology push could finally begin to dominate the investment narrative. Until then, Siemens Healthineers remains a story of promise weighed down by a problem child. New quarterly figures are due in July.